Citations

Clear

3030 citation(s) found for "Susan, M".

Development of an Electronic Health Record–Based Clinical Decision Support Tool for Patients With Lynch Syndrome
Lau‐Min, Kelsey S. , Bleznuck, Joseph, Wollack, Colin, McKenna, Danielle , Long, Jessica M. , Hubert, Anna P. , Johnson, Mariah, Rochester, Shavon E., Constantino, Gillain , Dudzik, Christina , Doucette, Abigail , Wangensteen, Kirk J. , Landgraf, Jeffrey, Chen, Jessica , Nathanson, Katherine L. , McKenna, Danielle B , Wangensteen, Kirk J , Domchek, Susan M , Nathanson, Katherine L , Katona, Bryson W , Domchek, Susan M.

Mayo Clinic

JCO Clinical Cancer Informatics | August 28, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/cci.23.00024 | PMID 37639653 Get It

PURPOSE To develop an electronic health record (EHR)–based clinical decision support (CDS) tool to promote guideline-recommended cancer risk management among patients with Lynch syndrome (LS), an inherited cancer syndrome that confers an increased risk of colorectal and other cancer types. MATERIALS AND METHODS We conducted a cross-sectional study to determine the baseline prevalence and predictors of guideline-recommended colonic surveillance and annual genetics program visits among patients with LS. Multivariable log-binomial regressions estimated prevalence ratios (PRs) of cancer risk management adherence by baseline sociodemographic and clinical characteristics. These analyses provided rationale for the development of an EHR-based CDS tool to support patients and clinicians with LS-related endoscopic surveillance and annual genetics program visits. The CDS leverages an EHR platform linking discrete genetic data to LS Genomic Indicators, in turn driving downstream clinician- and patient-facing CDS. RESULTS Among 323 patients with LS, cross-sectional adherence to colonic surveillance and annual genetics program visits was 69.3% and 55.4%, respectively. Patients with recent electronic patient portal use were more likely to be adherent to colonic surveillance (PR, 1.67; 95% CI, 1.11 to 2.52). Patients more recently diagnosed with LS were more likely to be adherent to annual genetics program visits (PR, 0.58; 95% CI, 0.44 to 0.76 for 2-4 years; PR, 0.62; 95% CI, 0.51 to 0.75 for ≥4 compared with <2 years). Our EHR-based CDS tool is now active for 421 patients with LS throughout our health system. CONCLUSION We have successfully developed an EHR-based CDS tool to promote guideline-recommended cancer risk management among patients with LS.
Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data
Parsons, Susan K. , Thanarajasingam, Gita , Thompson, Carrie A. , Thompson, Carrie, K Parsons, Susan , Pophali, Priyanka A. , Morton, Lindsay M. , Hodgson, David , Habermann, Thomas M. , Savage, Kerry J.

Mayo Clinic

eJHaem | August 25, 2023 | Volume: 4 | Issue: 4 | Pages: 927-933

10.1002/jha2.778 | PMID 38024619 Get It

AbstractAdolescents and young adults (AYA) with lymphoma experience treatment‐related effects in the short and long term that impact their quality of life and survivorship experience. The effort to improve outcomes for AYA lymphoma survivors requires understanding the available literature, identifying current knowledge deficits, designing better clinical trials incorporating the patient perspective, using novel tools to bridge data gaps and building survivorship guidelines that translate research to clinical practice. This review article summarizes the current state of lymphoma treatment‐related outcomes in AYAs and provides future direction.
Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment
Kosydar, Samuel , Parikh, Sameer A. , Rabe, Kari G. , Ding, Wei , Burlile, Jessica F. , Kenderian, Saad S. , Wang, Yucai , Muchtar, Eli , Koehler, Amber B. , Schwager, Susan M., Call, Timothy G. , Breen, William G. , Hampel, Paul J. , Kosydar, Samuel R , Lester, Scott C. , Chaffee, Kari G. , Ding, Wei , Burlile, Jessica , Kenderian, Saad Sirop , Wang, Yucai , Muchtar, E , Hampel, Paul J , Parikh, Sameer A , Slager, Susan L. , Kay, Neil E.

Mayo Clinic

American Journal of Hematology | August 24, 2023 | Volume: 98 | Issue: 11 | Pages: No page available

10.1002/ajh.27060 | PMID 37614209 Get It

Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Page, David B. , Broeckx, Glenn , Jahangir, Chowdhury Arif , Verbandt, Sara , Gupta, Rajarsi , Thagaard, Jeppe , Khiroya, Reena, Kos, Zuzana , Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Bouchmaa, Najat , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Portela, Flávio Luis Dantas , Deman, Frederik , Dudgeon, Sarah , Elghazawy, Mahmoud , Ely, Scott , Fernandez‐Martín, Claudio , Fineberg, Susan , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hardas, Alexandros , Hartman, Johan , Hewitt, Stephen M. , Hida, Akira I. , Husain, Zaheed, Hytopoulos, Evangelos, Irshad, Sheeba , Janssen, Emiel A. M., Kahila, Mohamed, Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Durga, Kharidehal, Khramtsov, Andrey , Kirtani, Pawan, Korski, Konstanty, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Michiels, Stefan, Mittal, Shachi , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Salto‐Tellez, Manuel , Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Sughayer, Maher A. , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Teuwen, Jonas, Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Laak, Jeroen van der , Verghese, Gregory , Viale, Giuseppe , Vieth, Michael, Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Yuan, Yinyin, Bartlett, John Mark Seaverns, Loibl, Sibylle , Loi, Sherene , Salgado, Roberto , Stovgaard, Elisabeth Specht , Symmans, W. Fraser , Kahila, Mohamed M. , Gupta, Rajarsi R , Dantas Portela, Flavio Luis , Elghazawy, Mahmoud , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Chardas, Alexandros , Hart, Steven N , Hartman, Johan , Kataoka, Tatsuki R , Rau, Tilman T , Reis-Filho, Jorge S , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Symmans, W Fraser , Lennerz, Jochen , Loi, Sherene , Acs, Balazs , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , AbdulJabbar, Khalid , Aktürk, Güray , Almeida, Jonas S. , Ardalan, Farid Azmoudeh , Badve, Sunil, Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Gallagher, William M. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Kovács, Anikó , Lerousseau, Marvin , Ly, Amy , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Moore, David , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rahman, Arman , Rajpoot, Nasir , Rapoport, Bernardo L. , Reis‐Filho, Jorge S. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sur, Daniel Genel , Tran, William T, Diest, P. J. van , Yuan, Yinyin , Adams, Sylvia , Bartlett, John M.S. , Denkert, Carsten , Savas, Peter Stephen

Mayo Clinic

The Journal of Pathology | August 23, 2023 | Volume: 260 | Issue: 5 | Pages: 514-532

10.1002/path.6165 | PMID 37608771 Get It

Abstract Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized method for describing or analyzing spatial immune cell data, and most reported spatial analyses are rudimentary. In this review, we provide an overview of two approaches for reporting and analyzing spatial data (raster versus vector‐based). We then provide a compendium of spatial immune cell metrics that have been reported in the literature, summarizing prognostic associations in the context of a variety of cancers. We conclude by discussing two well‐described clinical biomarkers, the breast cancer stromal tumor infiltrating lymphocytes score and the colon cancer Immunoscore, and describe investigative opportunities to improve clinical utility of these spatial biomarkers. © 2023 The Pathological Society of Great Britain and Ireland.
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Thagaard, Jeppe , Broeckx, Glenn , Page, David B. , Jahangir, Chowdhury Arif , Verbandt, Sara , Kos, Zuzana , Gupta, Rajarsi , Khiroya, Reena, Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Balslev, Eva , Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Bouchmaa, Najat , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Dahl, Anders Bjorholm , Portela, Flávio Luis Dantas , Deman, Frederik , Hansen, Johan Doré, Dudgeon, Sarah , Ebstrup, Thomas, Elghazawy, Mahmoud , Fernandez‐Martín, Claudio , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hartman, Johan , Hauberg, Søren , Hewitt, Stephen M. , Hida, Akira I. , Husain, Zaheed, Hytopoulos, Evangelos, Irshad, Sheeba , Janssen, Emiel A. M., Kahila, Mohamed M. , Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Durga, Kharidehal, Khramtsov, Andrey , Kirtani, Pawan , Korski, Konstanty, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Mittal, Shachi , Moore, David A. , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Penault‐Llorca, Frédérique, Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Roslind, Anne, Salto‐Tellez, Manuel , Scott, Ely, Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Sughayer, Maher A. , Fineberg, Susan , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Laak, Jeroen van der , Verghese, Gregory , Viale, Giuseppe , Vieth, Michael, Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Zin, Reena Md, Bartlett, John M.S. , Loibl, Sibylle , Loi, Sherene , Salgado, Roberto , Stovgaard, Elisabeth Specht , Symmans, W. Fraser , Acs, Balazs , Chardas, Alexandros , Dantas Portela, Flavio Luis , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Hart, Steven N , Kataoka, Tatsuki R , Rau, Tilman T , Reis-Filho, Jorge S , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Symmans, W Fraser , Lennerz, Jochen , Loi, Sherene , Hartman, Johan , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , AbdulJabbar, Khalid , Aktürk, Güray , Almeida, Jonas S. , Amgad, Mohamed T. , Ardalan, Farid Azmoudeh , Badve, Sunil , Hardas, Alexandros , Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Gallagher, William M. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Kovács, Anikó , Lerousseau, Marvin , Ly, Amy , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rahman, Arman , Rajpoot, Nasir , Rapoport, Bernardo L. , Reis‐Filho, Jorge S. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sur, Daniel Genel , Teuwen, Jonas , Tran, William T, Diest, P. J. van , Yuan, Yinyin , Adams, Sylvia , Denkert, Carsten , Savas, Peter Stephen

Mayo Clinic

The Journal of Pathology | August 23, 2023 | Volume: 260 | Issue: 5 | Pages: 498-513

10.1002/path.6155 | PMID 37608772 Get It

AbstractThe clinical significance of the tumor‐immune interaction in breast cancer is now established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple‐negative (estrogen receptor, progesterone receptor, and HER2‐negative) breast cancer and HER2‐positive breast cancer. How computational assessments of TILs might complement manual TIL assessment in trial and daily practices is currently debated. Recent efforts to use machine learning (ML) to automatically evaluate TILs have shown promising results. We review state‐of‐the‐art approaches and identify pitfalls and challenges of automated TIL evaluation by studying the root cause of ML discordances in comparison to manual TIL quantification. We categorize our findings into four main topics: (1) technical slide issues, (2) ML and image analysis aspects, (3) data challenges, and (4) validation issues. The main reason for discordant assessments is the inclusion of false‐positive areas or cells identified by performance on certain tissue patterns or design choices in the computational implementation. To aid the adoption of ML for TIL assessment, we provide an in‐depth discussion of ML and image analysis, including validation issues that need to be considered before reliable computational reporting of TILs can be incorporated into the trial and routine clinical management of patients with triple‐negative breast cancer. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
Steiner, Raphaël , Hwang, Steven R. , Khurana, Arushi , Annunzio, Kaitlin , Allen, Pamela B. , Baird, Katelin , Paulino, Darina, Alderuccio, Juan Pablo , Lossos, Izidore S. , David, Kevin A. , Evens, Andrew M. , Pandya, Karan, Bair, Steven M. , Kamdar, Manali , Aqeel, Sheeba Ba, Torka, Pallawi , Lynch, Ryan C. , Smith, Stephen D. , Noorani, Mansoor, Nair, Ranjit, Fang, Penny , Dabaja, Bouthaina S. , Lee, Hun Ju , Epperla, Narendranath , Allen, Pamela Blair , Baird, Katelin , Alderuccio, Juan Pablo , Lossos, Izidore S , David, Kevin , Evens, Andrew M , Kamdar, Manali , Torka, Pallawi , Smith, Stephen D , Ahmed, Sairah , Vega, Francisco , Lee, Hun Ju , Hwang, Steven R , Habermann, Thomas M. , Epperla, Narendranath , Feng, Lei , Ahmed, Sairah , Vega, Francisco , Wu, Susan Y. , Pinnix, Chelsea C. , Gunther, Jillian Rebecca

Mayo Clinic

Blood Advances | August 21, 2023 | Volume: 7 | Issue: 24 | Pages: 7485-7493

10.1182/bloodadvances.2023010700 | PMID 37603594 Get It

Abstract In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). However, there are minimal available data regarding the frequency of dose reductions or omission of BV during curative therapy and the potential impact on patient outcomes. In a real-world analysis, we retrospectively reviewed the characteristics and outcomes of 179 patients with stage III or IV cHL treated with frontline A + AVD from January 2010 to April 2022. Treatment consisted of up to 1.2 mg/kg of BV and standard dose AVD IV on days 1 and 15 of each 28-day cycle for up to 6 cycles. At the time of treatment, the median patient age was 37 years, and a high-risk International Prognostic Score was observed in 46% of patients. Overall, 91% of patients received 6 cycles of AVD; 55% of patients did not receive the intended cumulative dose of BV (CDB); 28% of patients received two-thirds or less than the planned CDB. At a median follow-up time of 27.4 months (95% confidence interval [CI], 24.8-29), the median progression-free survival (PFS) was not reached, and the 12-month PFS was 90.3% (95% CI, 85.9-95.0). The impact of CDB on PFS was not significant (P = .15), nor was high CDB significantly associated with increased adverse events. In real-world experience, A + AVD is a highly effective treatment for patients with advanced-stage cHL, including for patients with prominent dose reductions of BV.
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
Acosta‐Medina, Aldo A. , Kemps, Paul G. , Zondag, Timo C. E. , Abeykoon, Jithma P. , Forma-Borst, Jelske, Steenwijk, Eline C., Feijen, Elizabeth A. M. , Teepen, Jop C. , Bennani, N. Nora , Schram, Susan, Davidge‐Pitts, Caroline , Ryu, Jay H. , Vassallo, Robert , Dasari, Surendra , Ravindran, Aishwarya , Cleven, Arjen H.G. , Balgobind, Brian V. , Saeed, Peerooz , Bramer, Jos A. M. , Groen, Ruben A. L. de , Tonino, Sanne H. , Bos, Cor van den , Laar, Jan van , Halteren, Astrid G. S. van , Schram, Susan M, Shah, Mithun V , Davidge-Pitts, Caroline , Koster, Matthew J , Ryu, Jay H , Tobin, W Oliver , Young, Jason R , Dasari, Surendra , Rech, Karen , Ravindran, Aishwarya , Cleven, Arjen H G , Verdijk, Robert M , van Noesel, Carel J M , Balgobind, Brian V , Bouma, Gerrit Joan , Saeed, Peerooz , Bramer, Jos A M , de Groen, Ruben A L , Vermaat, Joost S P , van de Sande, Michiel A J , Smit, Egbert F , Langerak, Anton W , van Wezel, Tom , Tonino, Sanne H , van den Bos, Cor , van Laar, Jan A M , Go, Ronald S , Goyal, Guarav , van Halteren, Astrid G S , Vassallo, Robert , Bennani, N Nora , Acosta-Medina, Aldo A , Shah, Meera , Koster, Matthew J. , Tobin, W. Oliver , Young, Jason R. , Rech, Karen L. , Verdijk, Robert M. , Noesel, Carel J.M. van , Sande, Michiel A. J. van de , Langerak, Anton W. , Go, Ronald S. , Goyal, Gaurav

Mayo Clinic

Blood | August 18, 2023 | Volume: 142 | Issue: 18 | Pages: 1570-1575

10.1182/blood.2023021212 | PMID 37595284 Get It

Abstract In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clonally related.
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Hsu, Chih–Yuan , Shah, Surbhi, Zon, Rebecca L. , Alsamarai, Susan, El-Bakouny, Ziad, Beeghly, Alicia, Doroshow, Deborah B. , Flora, Daniel , Fromowitz, Ariel, Jani, Chinmay , Khan, Hina, Klein, Elizabeth J. , Heater, Natalie Knox , Koshkin, Vadim S. , Kwon, Daniel H. , McKay, Rana R. , Nonato, Taylor K., Polimera, Hyma , Puc, Matthew , Shastri, Aditi , Singh, Sunny , Weissmann, Lisa B., Wilkins, Cy R. , Yoon, James J., Mishra, Sanjay , Grivas, Petros , Connors, Jean M. , Gandhi, Rikin, Gartrell, Benjamin A. , Makower, Della , Sullivan, Darciann O', Ohri, Nitin , Verma, Amit , Butt, Omar H. , Fiala, Mark A. , Monahan, Ryan, Bitran, Jacob D. , Hallmeyer, Sigrun , Mundt, Daniel , Pandravada, Sasirekha, Papaioannou, Philip V., Patel, Mauli, Streckfuss, Mitrianna, Tadesse, Eyob, Lammers, Philip E. , Bindal, Poorva , Lam, Barbara C.C., Piper‐Vallillo, Andrew J., Arvanitis, Panos , Vieira, Kendra, Angevine, Anne H., Bär, Michael, Prete, Salvatore A. Del , Fiebach, Maryann Z., Gulati, Anthony P., Hatton, Edward H., Houston, Kaly, Lo, K. M. Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Routy, Bertrand , Hoyo-Ulloa, Irma , Gupta, Shilpa , Sharifi, Nima , Hoppenot, Claire , Demetri, George D., Zarif, Talal El , Freeman, Dory , Nohria, Anju, Tolaney, Sara M. , Zhang, Tian , Dzimitrowicz, Hannah, Leighton, John, Lynch, Ryan C. , Portuguese, Andrew J. , Schweizer, Michael T. , Vinayak, Shaveta , Wagner, Michael J. , Dansoa, Yvonne , Manikowski, Jesse J. , Vadakara, Joseph , Yossef, Kristena, Beckerman, Jennifer, Goyal, Sharad , Messing, Ian , Provenzano, Destie , Steffes, Dawn R., Clément, Jessica , Cosin, Jonathan A. , Daher, Ahmad , Dailey, Mark E., Hosmer, Wylie, Hsu, Emily , Jayaraj, Asha, Mather, Jeff, Menendez, Alvaro G. , Nadkarni, Rajani, Serrano, Oscar K. , Tejwani, Sheela , Accordino, Melissa , Bodin, Brianne E, Khan, Shaheer , Masson, Cynthia, Alexander, Mariam , Matar, Sara , Bernicker, Eric , Deeken, John F. , Jeffords, Kelly J., Shafer, Danielle , Cárdenas‐Delgado, Ana I., Campos, Rogelio Cuervo, Ramirez, Ana, Valdez-Reyes, Nadia Melissa, Gill, David , Lewis, Mark A. , Low, Clarke A., Rhodes, Terence D., Jones, Michelle, Mansoor, Abdul-Hai, Mashru, Sandeep H., Werner, Mica A., Cohen, Aaron , Hayes‐Lattin, Brandon , Nemecek, Eneida R. , Williamson, Staci, Lewis, Grant C., Smith, Stephanie J., Akhtari, Mojtaba, Castillo, Dan R., Cortez, Kimberly, Park, Kyu, Reeves, Mark E. , O’Connor, Timothy E. , Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Ramesh, Vidhyalakshmi , Wilson, Grace L. , Bardia, Aditya , Gainor, Justin F. , Peppercorn, Jeffrey , Reynolds, Kerry L. , Zubiri, Leyre , Campian, Jian , Riaz, Irbaz B, Williams, Colt , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Wang, Chen‐Pin , Bouganim, Nathaniel , Elkrief, Arielle , Moria, Feras, Panasci, Justin , Nanchal, Rahul , Bahadur, Nadia , Nambiar, Puja H. , Papadopoulos, Esperanza B. , Riely, Gregory J. , Rosenberg, Jonathan E., Cerrone, Kim, Dill, Jennifer A. , Faller, Bryan A. , Ajmera, Archana , Brouha, Sharon S. , Choi, Sharon , Bhatt, Padmanabh , Mariano, Melissa G., Thomson, Carey C. , Glace, Mary Grace, Knoble, Jeanna, Zacks, Rosemary, Blau, Sibel , Brown, CarrieAnn, Namburi, Swathi, Pomerantz, Lauren , Rovito, Marc A., Advani, Pragati E., Cronin, Tara, Fleissner, Bridget, Goel, Shipra , Gopalakrishnan, Dharmesh , Hernandez‐Ilizaliturri, Francisco J. , Kariapper, Ariffa, Levine, Ellis , Wicher, Camille P., Misdary, Christian, Shah, Mansi , Batist, Gerald , Cook, Erin , Esfahani, Khashayar , Ferrario, Cristiano , Lau, Susie , Ma, Kim, Rudski, Lawrence , Dutra, Míriam Santos , Mahmood, Sana , Mico, Vasil, Rivera, Andrea Verghese, Dixon, Becky, Heilman, Hannah, Logan, Barbara, Mandapakala, Chaitanya, Cabebe, Elwyn C., Glover, Michael , Jha, Alokkumar , Schapira, Lidia , Shah, Sumit , Subbiah, Suki , Lopes, Gilberto , Cardenas, Karen de, Russell, Karen , Stith, Brittany, Taylor, Sharona, Klamerus, Justin F., Revankar, Sanjay G. , Addison, Daniel , Chen, James L. , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Abbasi, Saqib Hussen, Annis, Sandy, Greenland, Steven, Jones, Regina, Kasi, Anup , Rock, Crosby D. , Wulff‐Burchfield, Elizabeth , Smits, Melissa, Weiß, Matthias , Chism, David D. , Owenby, Susie, Ang, Celina , Galsky, Matthew D. , Metzger, Megan , Uyehara, Catherine, Lashley, Latoya N., Sueyoshi, Mark, Patel, Kanishka G. , Riess, Jonathan W. , Borno, Hala T. , Rubinstein, Samuel M. , Ahmad, Syed A. , Grover, Punita , Jandarov, Roman , Kharofa, Jordan , Marcum, Michelle, Sohal, Davendra , Zamulko, Olga , Balmaceda, Nicole , Geiger, Christopher L., Russ, Atlantis Dawn, Saker, Haneen , Choi, Horyun, Feldman, Lawrence , Gantt, Gerald, Hoskins, Kent , Khan, Mahir, Liu, Li , Nguyen, Ryan H., Schwartz, Candice, Venepalli, Neeta K. , Boldt, Anne, Fecher, Leslie A. , Su, Chris, Bijjula, Ragneel R., Mavromatis, Blanche H., Seletyn, Mildred E., Wood, Barbara R., Kaklamani, Virginia , Charles, Lawrence J., Cheng, Alex , Ding, Tan , Enriquez, Kyle T. , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Lewis, Judy T., Reid, Sonya , Saif, Sara, Slosky, David, Solórzano, Carmen C. , Sun, Tianyi , Yang, Yuanchu James , Carducci, Theresa M., Goldsmith, Karen J., Loon, Susan Van, Topaloĝlu, Ümit , Moore, Joan K., Cabalona, Wilhelmina D., Shisler, Elizabeth, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Bilen, Mehmet Asım , Castellano, Cecilia A. , Ravindranathan, Deepak , LoRusso, Patricia , Lustberg, Maryam B. , Masters, Tyler, Mishra, Sanjay , Zubiri, Leyre , Fiala, Mark A , Bilen, Mehmet A , Portuguese, Andrew J , Lustberg, Maryam , Gulati, Shuchi , Shah, Pankil , Awosika, Joy A. , Bashir, Babar , Berg, Stephanie , De‐la‐Rosa‐Martinez, Daniel , Egan, Pamela , Fein, Joshua Alexander , Friese, Christopher R. , Griffiths, Elizabeth A. , Hwang, Clara , Joshi, Monika , Labaki, Chris , Latif, Tahir , Nagaraj, Gayathri , Nakasone, Elizabeth S. , Razavi, Pedram , Ruíz‐García, Erika , Saliby, Renée Maria , Tagalakis, Vicky , Vilar‐Compte, Diana , Wise-Draper, Trisha Michel , Wotman, Michael T. , Shyr, Yu , Warner, Jeremy L. , Shah, Dimpy P. , Rosovsky, Rachel , Goel, Sanjay , Halmos, Balázs , Sica, Roberto Alejandro , Henderson, Jeffrey P. , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Thompson, Michael A. , Loree, Jonathan M. , Lam, Barbara, Peters, Mary Linton B , Farmakiotis, Dimitrios , Olszewski, Adam J. , Hatton, Edward, Rose, Suzanne J. , Nizam, Amanda , Pennell, Nathan A , Li, Ang , Bitterman, Danielle S. , Choueiri, Toni K. , Florez, Narjust , Giordano, Antonio , Morgans, Alicia K. , Nohria, Anju , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Graber, Jerome J. , Hawley, Jessica E. , Loggers, Elizabeth T , Lyman, Gary H , Su, Christopher , Tachiki, Lisa , Yeh, Albert C. , Gatson, Na Tosha , Makary, Mina S. , Rao, Yuan James , Rosenstein, Lori J. , Elias, Rawad , Eton, Omar , Yu, Peter Paul , Gadgeel, Shirish M. , Bhutani, Divaya , Hershman, Dawn L. , Ingham, Matthew , Schwartz, Gary K. , Reuben, Daniel Y. , McWeeney, Shannon K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Sachs, Zohar , Wilson, Grace, Boland, Genevieve M. , Smith, Katherine E. , Bekaii‐Saab, Tanios , Desai, Aakash , Hálfdánarson, Þorvarður R. , Joyner, Michael J. , Senefeld, Jonathon W. , Ramirez, Amelie G , Mesa, Ruben A. , Papenburg, Jesse , Vinh, Donald Cuong , Singh, Harpreet , Bao, Ting , O'Cearbhaill, Roisin E , Philip, John, Robson, Mark E. , Rosenberg, Jonathan E., Schoenfeld, Adam Jacob , Tamimi, Rulla M. , Dill, Jennifer, Hsiao, Albert , Reid, Erin G , Rink, Cameron L. , Jain, Prantesh , Moffitt, Melissa , O’Connor, Tracey L. , Puzanov, Igor , Smith, Laurie J., Zsíros, Emese , Jabbour, Salma K , Cook, Erin, Miller, Wilson H. , Wilchesky, Machelle , McNair, Christopher M. , Khaki, Ali Raza , Nagpal, Seema , Wu, Julie , Whaley, David, Gatti-Mays, Margaret Elena , Jhawar, Sachin R. , Palmer, Joshua D. , Stover, Daniel G. , Weiss, Matthias, Berenberg, Jeffrey L. , Fazio, Alyson, Huber, Kathryn E. , Small, Eric J. , Zhang, Sylvia , Andermann, Tessa M. , Jensen, Christopher Edward , Wood, William A. , Li, Ningjing , Abidi, Maheen Z. , Bowles, Daniel W. , Markham, Merry Jennifer , Acoba, Jared David , Rho, Young Soo, Nguyen, Ryan H., Pasquinelli, Mary M. , Vikas, Praveen , Zakharia, Yousef , Zaman, Qamar U., Brown, Alaina J. , Crispens, Marta Ann , Croessmann, Sarah , Davis, Elizabeth J. , Ding, Tan, Duda, Stephany N. , Hausrath, Daniel J. , Li, Xuanyi , Prescott, Lauren Shore , Wang, Lucy Lu , Aboulafia, David M. , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine , Painter, Corrie , Peters, Solange

Mayo Clinic

JAMA Oncology | August 17, 2023 | Volume: 9 | Issue: 10 | Pages: 1390

10.1001/jamaoncol.2023.2934 | PMID 37589970 Get It

ImportanceSystematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking.ObjectiveTo assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer.Design, Setting, and ParticipantsThis registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022.ExposureTreatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19.Main Outcomes and MeasuresMain outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up.ResultsOf 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing cancer (aRR, 1.43; 95% CI, 1.01-2.03), history of VTE (aRR, 3.10; 95% CI, 2.38-4.04), and high-risk site of cancer (aRR, 1.42; 95% CI, 1.14-1.75). Black patients had a higher risk of TEEs (aRR, 1.24; 95% CI, 1.03-1.50) than White patients. Patients with TEEs had high intensive care unit admission (46%) and mechanical ventilation (31%) rates. Relative risk of death in patients with TEEs was higher in those exposed to TOIs vs not (aRR, 1.12; 95% CI, 0.91-1.38) and was significantly associated with poor performance status (aRR, 1.77; 95% CI, 1.30-2.40) and active/progressing cancer (aRR, 1.55; 95% CI, 1.13-2.13).Conclusions and RelevanceIn this cohort study, relative risk of developing VTE was high among patients receiving TOIs and varied by the type of therapy, underlying risk factors, and demographics, such as race and ethnicity. These findings highlight the need for close monitoring and perhaps personalized thromboprophylaxis to prevent morbidity and mortality associated with COVID-19–related thromboembolism in patients with cancer.
Antidepressant-Associated Treatment Emergent Mania
Núñez, Nicolás A. , Özerdem, Ayşegül , Singh, Balwinder , Prieto, Miguel L. , Frye, Mark A. , Melhuish Beaupre, Lindsay, Singh, Balwinder , Ozerdem, Aysegul , Coombes, Brandon J. , Beaupre, Lindsay Melhuish , Romo‐Nava, Francisco , Gardea‐Resendez, Manuel , Veldić, Marin , Sánchez-Ruiz, Jorge A. , Cuéllar‐Barboza, Alfredo B. , Leung, Jonathan G. , McElroy, Susan L. , Biernacka, Joanna M.

Mayo Clinic

Journal of Clinical Psychopharmacology | August 16, 2023 | Volume: 43 | Issue: 5 | Pages: 428-433

10.1097/jcp.0000000000001747 | PMID 37683232 Get It

Abstract Background The purpose of this study was to review the association between the SLC6A4 5-HTTLPR polymorphism and antidepressant (AD)-associated treatment emergent mania (TEM) in bipolar disorder alongside starting a discussion on the merits of developing risk stratification models to guide when not to provide AD treatment for bipolar depression. Methods Studies that examined the association between clinical and genetic risk factors, specifically monoaminergic transporter genetic variation, and TEM were identified. A meta-analysis was performed using the odds ratio to estimate the effect size under the Der-Simonian and Laird model. Results Seven studies, referencing the SLC6A4 5-HTTLPR polymorphism and TEM (total N = 1578; TEM+ =594, TEM− = 984), of 142 identified articles were included. The time duration between the start of the AD to emergence of TEM ranged from 4 to 12 weeks. There was a nominally significant association between the s allele of the 5-HTTLPR polymorphism and TEM (odds ratio, 1.434; 95% confidence interval, 1.001–2.055; P = 0.0493; I 2 = 52%). No studies have investigated norepinephrine or dopamine transporters. Conclusion Although the serotonin transporter genetic variation is commercially available in pharmacogenomic decision support tools, greater efforts, more broadly, should focus on complete genome-wide approaches to determine genetic variants that may contribute to TEM. Moreover, these data are exemplary to the merits of developing risk stratification models, which include both clinical and biological risk factors, to guide when not to use ADs in bipolar disorder. Future studies will need to validate new risk models that best inform the development of personalized medicine best practices treating bipolar depression.
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD
Leiding, Jennifer W. , Arnold, Danielle E. , Parikh, Suhag , Logan, Brent R. , Marsh, Rebecca , Griffith, Linda M. , Wu, Ruizhe , Kidd, Sharon A. , Mallhi, Kanwaldeep , Chellapandian, Deepak , Lim, Stephanie Si , Grunebaum, Eyal , Falcone, Emilia Liana , Grossman, Debbi, Prasad, Vinod K. , Heimall, Jennifer , Burroughs, Lauri M. , Bleesing, Jack , Kapoor, Neena , Dara, Jasmeen , Williams, Olatundun , Kapadia, Malika, Oshrine, Benjamin , Rayes, Ahmad , Chong, Hey , Satter, Lisa Forbes , Martinez, Caridad , Lugt, Mark T. Vander , Yu, Lolie C. , Joshi, Avni Y. , Prockop, Susan E. , Aquino, Victor , Madden, Lisa, Milner, Jordan , Rangarajan, Hemalatha G. , Shah, Ami J. , Gillio, Alfred P. , Knutsen, Alan P. , Miller, Holly, Graham, Pamela, Bauchat, Andrea , Bunin, Nancy , Teira, Pierre , Petrović, Aleksandra , Chandra, Sharat , Abdel‐Azim, Hisham , Birbrayer, Olga, Cowan, Morton J. , Dvorak, Christopher C. , Pai, Sung‐Yun , Puck, Jennifer M. , Torgerson, Troy R. , Kang, Elizabeth M. , Si Lim, Stephanie J , Murguia-Favela, Luis , Prasad, Vinod K , Touzot, Fabien , Bednarski, Jeffrey J , Cuvelier, Geoffrey D E , Forbes Satter, Lisa R , Martinez, Caridad , Joshi, Avni, Prockop, Susan E , Dávila Saldaña, Blachy J , Broglie, Larisa A , Ebens, Christen L , Milner, Jordan , Rangarajan, Hemalatha G , Chandra, Sharat , Dorsey, Morna J , Cowan, Morton J , Dvorak, Christopher C , Haddad, Elie , Kohn, Donald B , Notarangelo, Luigi D , Puck, Jennifer M , Pulsipher, Michael A. , Torgerson, Troy R , Malech, Harry L , Kang, Elizabeth M , Parikh, Suhag , Leiding, Jennifer W , Shah, Ami J , Dara, Jasmeen , Cuvelier, Geoff D.E. , Chandrakasan, Shanmuganathan , Saldaña, Blachy J. Dávila , Broglie, Larisa , Ebens, Christen L. , DeSantes, Kenneth B , Moore, Theodore Bruce , Graham, Pamela, Dorsey, Morna J. , Haddad, Élie , Kohn, Donald B. , Malech, Harry L.

Mayo Clinic

Blood | August 10, 2023 | Volume: 142 | Issue: 24 | Pages: 2105-2118

10.1182/blood.2022019586 | PMID 37562003 Get It

Abstract Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation (HCT) is the definitive treatment for CGD, but questions remain regarding patient selection and impact of active disease on transplant outcomes. We performed a multi-institutional retrospective and prospective study of 391 patients with CGD treated either conventionally (non-HCT) enrolled from 2004 to 2018 or with HCT from 1996 to 2018. Median follow-up after HCT was 3.7 years with a 3-year overall survival of 82% and event-free survival of 69%. In a multivariate analysis, a Lansky/Karnofsky score &lt;90 and use of HLA-mismatched donors negatively affected survival. Age, genotype, and oxidase status did not affect outcomes. Before HCT, patients had higher infection density, higher frequency of noninfectious lung and liver diseases, and more steroid use than conventionally treated patients; however, these issues did not adversely affect HCT survival. Presence of pre-HCT inflammatory conditions was associated with chronic graft-versus-host disease. Graft failure or receipt of a second HCT occurred in 17.6% of the patients and was associated with melphalan-based conditioning and/or early mixed chimerism. At 3 to 5 years after HCT, patients had improved growth and nutrition, resolved infections and inflammatory disease, and lower rates of antimicrobial prophylaxis or corticosteroid use compared with both their baseline and those of conventionally treated patients. HCT leads to durable resolution of CGD symptoms and lowers the burden of the disease. Patients with active infection or inflammation are candidates for transplants; HCT should be considered before the development of comorbidities that could affect performance status. This trial was registered at www.clinicaltrials.gov as #NCT02082353.